What is the most recent earnings date for GTBP stock?
GT BIOPHARMA INC (GTBP) last reported earnings on 3/2/2026.
NASDAQ:GTBP • US36254L3087
Past quarterly earnings results for GT BIOPHARMA INC (GTBP), including EPS and revenue actuals, analyst estimates, and surprise percentages. This page focuses on historical performance (not forecasts).
EPS & Revenue History (in USD): Actual vs estimated values, surprises, q2q growth and acceleration numbers quarterly history.
| Quarter | EPS | EPS Est | EPS Surprise | EPS Q2Q | Revenue | Revenue Est | Revenue Surprise | Revenue Q2Q |
|---|---|---|---|---|---|---|---|---|
| Q4 2025 | -0.02 | -0.22 | 91.09% | 98.80% | - | - | ||
| Q3 2025 | -0.79 | -0.39 | -103.82% | 71.31% | - | - | ||
| Q2 2025 | -0.52 | -0.69 | 25.03% | 81.12% | - | - | ||
| Q1 2025 | -0.33 | -0.65 | 49.45% | 79.88% | - | - | ||
| Q4 2024 | -1.66 | -1.58 | -5.00% | 24.20% | - | - | ||
| Q3 2024 | -2.75 | - | -53.00% | - | - | |||
| Q2 2024 | -2.75 | - | -83.60% | - | - | |||
| Q1 2024 | -1.64 | -2.75 | 40.45% | -446.67% | - | - | ||
| Q4 2023 | -2.19 | -2.75 | 20.48% | 59.44% | - | - | ||
| Q3 2023 | -1.80 | -3.06 | 41.18% | 72.73% | - | - | ||
| Q2 2023 | -1.50 | -3.06 | 50.98% | 50.00% | - | - | ||
| Q1 2023 | -0.30 | -4.44 | 93.24% | 94.12% | - | - | ||
| Q4 2022 | -5.40 | -5.36 | -0.84% | 65.38% | - | - | ||
| Q3 2022 | -6.60 | -3.37 | -96.08% | -15.79% | - | - | ||
| Q2 2022 | -3.00 | -5.36 | 43.98% | 23.08% | - | - | ||
| Q1 2022 | -5.10 | -9.49 | 46.24% | 90.71% | - | - | ||
| Q4 2021 | -15.60 | -6.32 | -146.68% | 84.66% | - | - | ||
| Q3 2021 | -5.70 | -6.43 | 11.30% | - | - | - | ||
| Q2 2021 | -3.90 | -8.47 | 53.93% | - | - | - | ||
| Q1 2021 | -54.90 | -7.50 | -632.29% | - | - | - | ||
| Q4 2020 | -101.70 | -1.38 | -7,285.62% | - | - | - | ||
| Q3 2020 | - | - | - | - | ||||
| Q2 2020 | - | - | - | - | ||||
| Q1 2020 | - | - | - | - |
Notes
GT BIOPHARMA INC (GTBP) last reported earnings on 3/2/2026.
GT BIOPHARMA INC (GTBP) beat EPS estimates and missed revenue estimates in the most recent quarter.
In the last 4 quarters, GT BIOPHARMA INC (GTBP) has beaten EPS estimates in 2 out of 4 releases.